TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the publication of a detailed review of its collaboration with U.S.-based Minnetronix, a world leader in high-precision medical device manufacturing. Published in the industry journal, Medical Design & Development, the article was co-authored by Tom Looby, Conavi Medical’s CEO and Darcy Hart, Minnetronix Medical’s Director of Optical Products.
Tag: Conavi Medical
China’s NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP
– Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to EOM –
JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies
– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries –
Conavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business Combination
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Conavi Medical Corp. (formerly, “Titan Medical Inc.”) (“the “Resulting Issuer” or the “Corporation”) (TSX: TMD; OTC: TMDIF) is pleased to announce the completion of the previously announced business combination between Conavi Medical Inc. (“Conavi”) and the Corporation in an all-stock transaction, which constituted a reverse takeover of the Corporation (the “Transaction”). The combined company (the Resulting Issuer) will focus on continuing to commercialize and develop Conavi’s Novasight Hybrid™ System designed to guide common minimally invasive coronary procedures.
Titan Provides Update on Planned Merger with Conavi
TORONTO, Ontario, April 22, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”). As previously announced, Titan has entered into a definitive amalgamation […]
Conavi Medical Announces Close of Financing to Bolster Novel Intravascular Imaging Technology
TORONTO, CA, September 18, 2023 – Conavi Medical, Inc. (www.conavi.com), a leader in hybrid intravascular imaging, is pleased to announce the close of $12.5 mil USD of funding, including participation from existing investors. The round was led by CPOINT Capital, which is a professional life science investment firm with an […]
Conavi Medical’s Novasight Hybrid System Now In Use at Sunnybrook Health Sciences Centre
Sunnybrook’s Schulich Heart Program to provide the latest innovative hybrid imaging of coronary arteries for complex cases TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, and Sunnybrook Health Sciences Centre, today announced that the Novasight Hybrid System is now being used […]
Conavi Medical Plans for Strategic Expansion in U.S. Market
TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, plans to expand the presence of its Novasight Hybrid System in the U.S. market in 2022 under the guidance of its new leadership team. Thomas Looby, chief executive officer, Conavi Medical, appointed in […]
Conavi Medical Enters into Funding Agreements for Over $20 Million to Support Commercialization of its Innovative Intravascular Image Guidance Technology
TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, has entered into agreements for over $20 million in funding to support commercialization and growth as it prepares its innovative Novasight Hybrid® System for market. The company aims to raise an additional $10 million […]



